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Smoking Increases Osteopontin Expression in
the Lung
Macrophages and Langerhans cells accumulate in fi-
brotic tissues of patients with smoking-related interstitial
lung diseases. To determine whether osteopontin, a che-
motactic agent for both macrophages and Langerhans
cells, mediates cell recruitment in smokers, Prasse et al
(Am J Pathol 2009, 174: 1683–1691) compared os-
teopontin levels in bronchoalveolar lavage from smokers
with diverse interstitial lung diseases, healthy smokers,
and healthy nonsmokers. They found high levels of os-
teopontin expression in patients with pulmonary Lang-
erhans cell histocytosis and desquamative interstitial
pneumonitis, whereas healthy smokers had lower levels,
and healthy nonsmokers produced no osteopontin. Os-
teopontin expression in alveolar macrophages could be
stimulated by nicotine treatment. In addition, osteopontin
overexpression in rat lung resulted in recruitment of mac-
rophages and Langerhans cells, resulting in symptoms
similar to pulmonary Langerhans cell histocytosis. These
results indicate that osteopontin may be pathogenic in
smoking-initiated lung disease.
Notch1 Signaling Contributes to Lung Fibrosis
An increase in the number of myofibroblasts contributes
to the extracellular matrix and fibrogenic cytokine pro-
duction that characterizes progressive pulmonary fibro-
sis. FIZZ1 (found in inflammatory zone 1) can induce
myofibroblast differentiation during pulmonary fibrosis
without affecting cell proliferation. Liu et al (Am J Pathol
2009, 174: 1745–1755) hypothesized that Notch1,
which regulates cell fate in numerous cell types, plays a
role in FIZZ1-mediated myofibroblast differentiation. They
found that the activated intracellular domain of Notch1
(NIC) increased expression of -smooth muscle actin in
fibroblasts and that mice with deficient Notch1 signaling
had decreased responses to FIZZ1 and impaired lung
fibrosis. Taken together, these data suggest a role for
Notch1 signaling in response to FIZZ1 during myofibro-
blast differentiation and provide a novel target for treat-
ment of pulmonary fibrosis.
SPARC (Secreted Protein Acidic and Rich in
Cysteine) in Glomerular Disease
Chronic glomerular disease is associated with significant
podocyte injury and loss. SPARC, a counteradhesive
protein, is up-regulated in podocytes on injury. To define
the role of SPARC in glomerular disease, Sussman et al
(Am J Pathol 2009, 174: 1827–1836) examined nephro-
toxic nephritis in mice deficient in SPARC as well as in
normal mice. They found that glomerulosclerosis was
reduced in SPARC-null mice compared with normal con-
trols, in part because of maintenance of podocytes. In
addition, SPARC-deficient podocytes were more resis-
tant to stress-induced detachment. These results indicate
that SPARC may play an instigating role in podocyte
detachment and glomerulosclerosis.
Gangliosides May Protect Against Parkinson’s
Disease
Accumulation of -synuclein is pathogenic in Parkinson’s
disease and other synucleopathies, such as dementia
with Lewy bodies (DLB) and multisystem atrophy. Gan-
gliosides, such as GM1, have been shown to inhibit
-synuclein aggregation. To elucidate the mechanism
that drives ganglioside-mediated protection of synucle-
opathies, Wei et al (Am J Pathol 2009, 174: 1891–1909)
treated DLB-linked neuroblastoma cells with D-threo-1-phe-
nyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), an
inhibitor of glycosyl ceramide synthase. These PDMP-
treated cells developed lysosomal disease characterized
by reduced lysosomal activity, enhanced lysosomal
membrane permeability, and decreased expression of
lysosomal membrane proteins. PDMP-mediated inhibi-
tion of the autophagy-lysosomal pathway resulted in both
accumulation of - and -synucleins and cellular cyto-
toxicity. Ganglioside treatment reversed this phenotype,
suggesting that gangliosides protect against the lysoso-
mal pathology of synucleopathies.
Suppressor of Cytokine Signaling (SOCS)-1
Inhibits Prostate Cancer Growth
SOCS family members are expressed in a variety of
cancers, including chronic myeloid leukemia, melanoma,
and prostate cancer. The role of the various SOCS family
members in carcinogenesis, however, may be tissue-
dependent. Neuwirt et al (Am J Pathol 2009, 174: 1921–
1930) identified SOCS-1 expression in multiple prostate
cancer cell lines as well as in tissues from prostate can-
cer patients. They found that SOCS-1 expression was
up-regulated in response to interleukin-6 or androgen
therapy and that inhibition of SOCS-1 expression stimu-
lated tumor cell growth through the activation of cyclins
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and cyclin-dependent kinases. SOCS-1, therefore, plays
a negative regulatory role in prostate cancer proliferation.
TIP30 Inhibits Lung Cancer Metastasis
TIP30 is a putative tumor suppressor with decreased
expression in numerous cancers including melanoma,
breast cancer, and colon cancer. To determine whether
TIP30 plays a role in lung cancer progression and me-
tastasis, Tong et al (Am J Pathol 2009, 174: 1931–1939)
examined TIP30 expression in paired cancerous and
noncancerous lung tissue. TIP30 expression was de-
creased in a third of non-small cell lung cancers com-
pared with normal controls, and reduced TIP30 expres-
sion correlated with lymph node metastasis. In addition,
inhibition of TIP30 expression promoted lung cancer me-
tastasis and angiogenesis in mice, possibly because of
increased levels of osteopontin, matrix metalloprotein-
ase-2, and vascular endothelial growth factor. These find-
ings highlight TIP30 as a potential new therapeutic for
metastatic lung cancer.
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